PGEN insider sale notice: 106,837 shares via Goldman Sachs, recent 67,523-share sale

Rhea-AI Filing Summary

Precigen, Inc. reported a Form 144 notice for the proposed sale of 106,837 shares of its common stock, with an aggregate market value of $351,493.73, to be sold through Goldman Sachs & Co. LLC on or about 09/30/2025. The shares were acquired as restricted stock units on 03/09/2024 and were granted as compensation.

The filing also discloses a recent sale by the same person: 67,523 shares were sold on 09/29/2025 for gross proceeds of $241,104.38. The filer represents that they are not aware of any undisclosed material adverse information about the issuer.

Positive

• Transparent disclosure of the proposed sale including share count, value, broker, and sale date
• Origin of shares documented as restricted stock units granted on 03/09/2024, clarifying the nature of the holding
• Broker identified (Goldman Sachs & Co. LLC), indicating an orderly sale channel

Negative

• Insider sale activity: 67,523 shares were sold on 09/29/2025 for $241,104.38, which investors may view as insider monetization

Insights

Securities Analyst

TL;DR: Insider proposes to sell 106,837 RSU-derived shares via Goldman Sachs; recent partial sale of 67,523 shares raised $241k.

This Form 144 discloses a routine Rule 144 notice tied to shares acquired as compensation on 03/09/2024. The planned sale amount (106,837 shares, $351,493.73) represents a small fraction of the 352,910,331 shares outstanding, indicating limited dilution or market impact. The prior sale on 09/29/2025 (67,523 shares, $241,104.38) is a factual record of recent disposition. From a trading-volume perspective, these transactions are consistent with orderly monetization of RSU compensation rather than a large-scale exit.

Corporate Governance Expert

TL;DR: Disclosure appears compliant with Rule 144; sale stems from compensation RSUs and includes required attestation about material nonpublic information.

The filing documents the origin of the securities

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	106837	351493.73	352910331	09/30/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/09/2024	Acquired as compensation -- Restricted Stock Units	The Issuer			106837	03/09/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jeffrey Kindler 20374 Seneca Meadows Parkway Germantown MD 20876	Common Stock	09/29/2025	67523	241104.38

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Precigen's (PGEN) Form 144 disclose?

The filing discloses a proposed sale of 106,837 common shares valued at $351,493.73 to be sold around 09/30/2025 through Goldman Sachs & Co. LLC.

How and when were the shares being sold by the PGEN filer acquired?

The shares were acquired as restricted stock units (RSUs) on 03/09/2024 and were granted as compensation.

Did the filer recently sell any Precigen shares?

Yes. The filer sold 67,523 shares on 09/29/2025 for gross proceeds of $241,104.38.

Which broker is handling the proposed sale in the Form 144?

The proposed sale is to be executed through Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY.

Does the filer state any undisclosed material information about Precigen?

By signing the notice, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.